Valuation: Cipher Pharmaceuticals Inc

Market Cap 343M 242M 216M 201M 182M 22.93B 346M 2.41B 943M 11.92B 907M 887M 38.26B P/E 2026 *
12x
P/E 2027 * 11.1x
Enterprise Value 343M 242M 216M 201M 182M 22.93B 346M 2.41B 943M 11.92B 907M 887M 38.26B EV / Sales 2026 *
4.84x
EV / Sales 2027 * 4.22x
Free-Float
57.46%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer - 2019-07-28
Director of Finance/CFO - 2024-08-09
Director of Finance/CFO - 2022-08-14
Director TitleAgeSince
Chairman - 2019-06-11
Director/Board Member 78 2023-06-20
Director/Board Member - 2023-06-20
Change 5-day change 1-year change 3-year change Capi.($)
-22.72%-5.31% - - 243M
-1.36%+0.78%+42.36%+91.48% 1,054B
-5.73%-2.42%+30.23%+58.50% 636B
-2.40%+2.88%+19.13%+85.43% 497B
-2.39%+0.03%+65.67%+36.51% 359B
-0.06%+2.86%+24.03%+41.07% 345B
-0.55%+1.81%+14.16%+36.31% 273B
-1.08%-0.52%-6.51%+8.40% 246B
-1.13%+2.54%+41.19%+45.32% 226B
-1.67%+2.56%+25.13%+90.50% 187B
Average -3.63%+2.35%+28.38%+54.83% 424.69B
Weighted average by Cap. -1.36%+2.32%+31.78%+63.43%

Financials

2026 *2027 *
Net sales 70.85M 49.87M 44.55M 41.52M 37.65M 4.73B 71.41M 497M 195M 2.46B 187M 183M 7.9B 81.35M 57.26M 51.15M 47.68M 43.23M 5.44B 81.99M 571M 224M 2.83B 215M 210M 9.07B
Net income 27.7M 19.5M 17.42M 16.23M 14.72M 1.85B 27.92M 194M 76.13M 963M 73.22M 71.62M 3.09B 31.76M 22.36M 19.97M 18.61M 16.88M 2.12B 32.01M 223M 87.3M 1.1B 83.96M 82.12M 3.54B
Net Debt - -
Logo Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cipher Pharmaceuticals Inc